Cargando…

Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter

BACKGROUND: The first‐line therapy is effective for the treatment of primary immune thrombocytopenia (ITP); however, maintaining the long‐term responses remains challenging. Low‐dose decitabine (DAC) has been adopted to treat refractory ITP, while its role in macrophage polarization has not been ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Xia, Xu, Pengcheng, Ji, Lili, Wu, Boting, Zhan, Yanxia, Zhuang, Xibing, Ou, Yang, Hua, Fanli, Sun, Lihua, Li, Feng, Wang, Xiangdong, Chen, Hao, Cheng, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366349/
https://www.ncbi.nlm.nih.gov/pubmed/37488670
http://dx.doi.org/10.1002/ctm2.1344
_version_ 1785077146882932736
author Shao, Xia
Xu, Pengcheng
Ji, Lili
Wu, Boting
Zhan, Yanxia
Zhuang, Xibing
Ou, Yang
Hua, Fanli
Sun, Lihua
Li, Feng
Wang, Xiangdong
Chen, Hao
Cheng, Yunfeng
author_facet Shao, Xia
Xu, Pengcheng
Ji, Lili
Wu, Boting
Zhan, Yanxia
Zhuang, Xibing
Ou, Yang
Hua, Fanli
Sun, Lihua
Li, Feng
Wang, Xiangdong
Chen, Hao
Cheng, Yunfeng
author_sort Shao, Xia
collection PubMed
description BACKGROUND: The first‐line therapy is effective for the treatment of primary immune thrombocytopenia (ITP); however, maintaining the long‐term responses remains challenging. Low‐dose decitabine (DAC) has been adopted to treat refractory ITP, while its role in macrophage polarization has not been fully understood. We aimed to investigate the mechanistic role of DAC in M2 macrophage polarization and evaluated its therapeutic effect in ITP. METHODS: The M2 monocytes were identified by flow cytometry from peripheral blood mononuclear cells in healthy controls (HCs) and ITP patients. The expression of PPARγ, Arg‐1, DNMT3b and NLRP3, together with IL‐10 plasma levels was measured to examine its function. Bisulfite‐sequencing PCR was used to evaluate the methylation status of PPARγ promoter, and the binding affinity of KLF4 was measured by Cut&Tag. A sh‐PPARγ THP‐1 cell line was created to verify if low‐dose DAC‐modulated M2 macrophage polarization was PPARγ‐dependent. The passive ITP models were used to investigate the therapeutic effects of low‐dose DAC and its role in modulating polarization and immunomodulatory function of macrophages. NLRP3 inflammasome and reactive oxygen species were also tested to understand the downstream of PPARγ. RESULTS: The M2 monocytes with impaired immunoregulation were observed in ITP. After high‐dose dexamethasone (HD‐DXM) treatment, M2 monocytes increased significantly with the elevated expression of PPARγ, Arg‐1 and IL‐10 in CR patients. Low‐dose DAC promoted M2 macrophage polarization in a PPARγ‐dependent way via demethylating the promoter of PPARγ, especially the KLF4 binding sites. Low‐dose DAC alleviated ITP mice by restoring the M1/M2 balance and fine‐tuning immunomodulatory function of macrophages. The downstream of the PPARγ modulation of M2 macrophage polarization might physiologically antagonize NLRP3 inflammasome. CONCLUSIONS: Low‐dose DAC promoted M2 macrophage polarization due to the demethylation within the promoter of PPARγ, thus enhanced the KLF4 binding affinity in ITP.
format Online
Article
Text
id pubmed-10366349
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103663492023-07-26 Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter Shao, Xia Xu, Pengcheng Ji, Lili Wu, Boting Zhan, Yanxia Zhuang, Xibing Ou, Yang Hua, Fanli Sun, Lihua Li, Feng Wang, Xiangdong Chen, Hao Cheng, Yunfeng Clin Transl Med Research Articles BACKGROUND: The first‐line therapy is effective for the treatment of primary immune thrombocytopenia (ITP); however, maintaining the long‐term responses remains challenging. Low‐dose decitabine (DAC) has been adopted to treat refractory ITP, while its role in macrophage polarization has not been fully understood. We aimed to investigate the mechanistic role of DAC in M2 macrophage polarization and evaluated its therapeutic effect in ITP. METHODS: The M2 monocytes were identified by flow cytometry from peripheral blood mononuclear cells in healthy controls (HCs) and ITP patients. The expression of PPARγ, Arg‐1, DNMT3b and NLRP3, together with IL‐10 plasma levels was measured to examine its function. Bisulfite‐sequencing PCR was used to evaluate the methylation status of PPARγ promoter, and the binding affinity of KLF4 was measured by Cut&Tag. A sh‐PPARγ THP‐1 cell line was created to verify if low‐dose DAC‐modulated M2 macrophage polarization was PPARγ‐dependent. The passive ITP models were used to investigate the therapeutic effects of low‐dose DAC and its role in modulating polarization and immunomodulatory function of macrophages. NLRP3 inflammasome and reactive oxygen species were also tested to understand the downstream of PPARγ. RESULTS: The M2 monocytes with impaired immunoregulation were observed in ITP. After high‐dose dexamethasone (HD‐DXM) treatment, M2 monocytes increased significantly with the elevated expression of PPARγ, Arg‐1 and IL‐10 in CR patients. Low‐dose DAC promoted M2 macrophage polarization in a PPARγ‐dependent way via demethylating the promoter of PPARγ, especially the KLF4 binding sites. Low‐dose DAC alleviated ITP mice by restoring the M1/M2 balance and fine‐tuning immunomodulatory function of macrophages. The downstream of the PPARγ modulation of M2 macrophage polarization might physiologically antagonize NLRP3 inflammasome. CONCLUSIONS: Low‐dose DAC promoted M2 macrophage polarization due to the demethylation within the promoter of PPARγ, thus enhanced the KLF4 binding affinity in ITP. John Wiley and Sons Inc. 2023-07-24 /pmc/articles/PMC10366349/ /pubmed/37488670 http://dx.doi.org/10.1002/ctm2.1344 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Shao, Xia
Xu, Pengcheng
Ji, Lili
Wu, Boting
Zhan, Yanxia
Zhuang, Xibing
Ou, Yang
Hua, Fanli
Sun, Lihua
Li, Feng
Wang, Xiangdong
Chen, Hao
Cheng, Yunfeng
Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter
title Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter
title_full Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter
title_fullStr Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter
title_full_unstemmed Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter
title_short Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter
title_sort low‐dose decitabine promotes m2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing klf4 binding to pparγ promoter
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366349/
https://www.ncbi.nlm.nih.gov/pubmed/37488670
http://dx.doi.org/10.1002/ctm2.1344
work_keys_str_mv AT shaoxia lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT xupengcheng lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT jilili lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT wuboting lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT zhanyanxia lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT zhuangxibing lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT ouyang lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT huafanli lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT sunlihua lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT lifeng lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT wangxiangdong lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT chenhao lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter
AT chengyunfeng lowdosedecitabinepromotesm2macrophagepolarizationinpatientswithprimaryimmunethrombocytopeniaviaenhancingklf4bindingtoppargpromoter